Neuroimaging in Neurodegenerative Diseases
Neuroimaging Modalities Overview
Mermaid diagram (expand to render)
Introduction
Overview
Neuroimaging has revolutionized the diagnosis, monitoring, and understanding of neurodegenerative diseases. From structural magnetic resonance imaging (MRI) that reveals patterns of brain atrophy, to molecular positron emission tomography (PET) that visualizes specific proteinopathies in vivo, imaging technologies provide critical biomarkers for clinical diagnosis, research, and therapeutic development. The integration of neuroimaging into diagnostic frameworks — including the 2024 revised alzheimers criteria — underscores its central role in modern neurology . [@jack2024]
Neuroimaging modalities can be broadly divided into structural imaging (MRI, CT), functional imaging (fMRI, SPECT), and molecular imaging (PET with amyloid, tau, and dopamine tracers). Each modality provides complementary information about brain structure, function, and molecular pathology, enabling clinicians and researchers to track disease progression, differentiate between overlapping clinical syndromes, and evaluate therapeutic responses. [@ref]
Structural Magnetic Resonance Imaging (MRI)
Principles and Techniques
Structural MRI uses strong magnetic fields and radiofrequency pulses to generate high-resolution images of brain anatomy. Key sequences used in neurodegeneration include: [@ducharme2020]
- T1-weighted imaging: Provides excellent gray-white matter contrast, enabling volumetric analysis and detection of cortical and subcortical atrophy
- T2-weighted and FLAIR imaging: Detects white matter hyperintensities, edema, and inflammatory changes
- Diffusion tensor imaging (DTI): Maps white matter tract integrity by measuring water diffusion directionality, revealing axonal degeneration and wallerian-degeneration
- Susceptibility-weighted imaging (SWI): Detects iron deposition, microbleeds, and calcification, useful in neurodegeneration-brain-iron-accumulation
Disease-Specific Atrophy Patterns
Each neurodegenerative disease exhibits characteristic patterns of brain atrophy on MRI: [@pyatigorskaya2020]
alzheimers: Medial temporal lobe atrophy, particularly of the hippocampus and entorhinal [cortex, is the hallmark finding. The Scheltens visual rating scale grades hippocampal atrophy from 0 (normal) to 4 (severe). Posterior cortical atrophy predominates in the posterior-cortical-atrophy variant, while asymmetric left temporal atrophy characterizes primary-progressive-aphasia . [@veitch2025]
ftd: The behavioral variant shows frontal and anterior temporal atrophy, often asymmetric. Semantic variant PPA demonstrates anterior temporal pole atrophy (left > right), while nonfluent variant PPA shows left inferior frontal and insular atrophy . [@veitch2024]
parkinsons: Subtle cortical thinning and subcortical volume loss in the substantia-nigra and striatum. Nigrosome-1 loss of the dorsolateral substantia-nigra on susceptibility-weighted imaging ("swallow tail sign" loss) can support diagnosis . [@pontecorvo2025]
huntington-pathway: Caudate nucleus and striatum atrophy are early and prominent, with cortical thinning following as the disease progresses. [@defined2021]
als: Upper motor neuron degeneration manifests as precentral gyrus atrophy. DTI reveals corticospinal tract degeneration with reduced fractional anisotropy. [@dennis2014]
multiple-system-atrophy: The "hot cross bun sign" in the pons (MSA-C) and putaminal atrophy with a rim of T2 hyperintensity (MSA-P) are characteristic findings. [@vrahatis2024]
progressive-supranuclear-palsy: Midbrain atrophy produces the "hummingbird sign" on sagittal view. The midbrain-to-pons ratio is reduced.
corticobasal-degeneration: Asymmetric frontoparietal cortical atrophy contralateral to the clinically more affected side.
Volumetric and Computational Analysis
Automated volumetric analysis using tools like FreeSurfer, FSL, and ANTs enables precise quantification of regional brain volumes. Longitudinal volumetric MRI is used in clinical trials to measure rates of whole-brain atrophy and regional volume loss as endpoints. The Alzheimer's Disease Neuroimaging Initiative (ADNI) has been instrumental in standardizing MRI protocols and establishing normative data for brain volumetrics across the Alzheimer's continuum .
Positron Emission Tomography (PET)
Amyloid PET
amyloid-pet imaging detects fibrillar amyloid-beta (amyloid-beta deposits in the brain using radioligands that bind to amyloid-beta plaques. Approved tracers include:
- ¹¹CPittsburgh Compound B (PiB): The first amyloid PET tracer, limited by the short half-life of carbon-11 (~20 minutes)
- ¹⁸FFlorbetapir (Amyvid): FDA-approved fluorine-18 tracer
- ¹⁸FFlorbetaben (Neuraceq): FDA-approved fluorine-18 tracer
- ¹⁸FFlutemetamol (Vizamyl): FDA-approved fluorine-18 tracer
amyloid-pet is positive 15-20 years before symptom onset in alzheimers, making it valuable for identifying presymptomatic individuals and enriching clinical trials. Amyloid positivity is now a requirement for enrollment in anti-amyloid therapeutic trials, such as those for lecanemab and donanemab. aria monitoring during anti-amyloid therapy also relies on neuroimaging .
Tau PET
tau-protein PET tracers bind to neurofibrillary-tangles composed of hyperphosphorylated tau protein]. The most widely used second-generation tracer is ¹⁸FMK-6240, along with ¹⁸FPI-2620, ¹⁸FGTP1, and ¹⁸Fflortaucipir (Tauvid) — the first FDA-approved tau PET tracer.
Tau PET signal correlates closely with cognitive decline and neurodegeneration in Alzheimer's Disease, often more strongly than amyloid PET. Tau PET staging follows braak-staging patterns, with early binding in the medial temporal lobe (Braak stages I-II) progressing to lateral temporal, parietal, and frontal cortices .
Challenges remain in tau PET imaging for non-AD tauopathies (psp, corticobasal-degeneration, Pick's disease), as current tracers have lower affinity for 4R tau isoforms and straight filaments.
FDG-PET
¹⁸FFluorodeoxyglucose (FDG) PET measures regional cerebral glucose metabolism, which serves as a proxy for synaptic activity and neuronal function. Disease-specific hypometabolic patterns include:
- Alzheimer's Disease: Temporoparietal and posterior cingulate hypometabolism
- FTD: Frontal and anterior temporal hypometabolism
- Lewy Body Dementia: Occipital hypometabolism (distinguishing from AD)
- PSP: Frontal and midbrain hypometabolism
FDG-PET is particularly useful for differentiating between neurodegenerative dementias when clinical presentation is atypical.
Dopaminergic Imaging
Dopamine transporter (DaT) SPECT using ¹²³Iioflupane (DaTscan) or PET with ¹⁸FDOPA visualizes presynaptic dopaminergic terminal integrity in the [striatum. Reduced uptake in the putamen is characteristic of neurodegenerative parkinsonism (parkinsons, msa, psp, CBD), distinguishing these from essential tremor, drug-induced parkinsonism, and psychogenic movement disorders. DaT imaging does not differentiate between the different parkinsonian syndromes.
neuroinflammation PET
Translocator protein (TSPO) PET tracers, such as ¹¹CPK11195 and second-generation tracers (¹¹CPBR28, ¹⁸FDPA-714), detect activated [microglia
Resting-State fMRI
Resting-state fMRI (rs-fMRI) measures spontaneous low-frequency fluctuations in blood-oxygen-level-dependent (BOLD) signal to map functional brain networks without task demands. Key findings in neurodegeneration include:
- Default mode network (DMN) disruption in Alzheimer's Disease, with reduced connectivity between the posterior cingulate cortex, precuneus, and medial prefrontal [cortex
- Salience network disruption in behavioral variant FTD, involving the anterior cingulate and frontoinsular cortex
- Sensorimotor network changes in ALS and parkinsons
- Compensatory hyperconnectivity in presymptomatic mutation carriers, suggesting functional reorganization before atrophy
Task-Based fMRI
Task-based fMRI paradigms, including memory encoding, executive function, and language tasks, reveal disease-specific patterns of hypoactivation and compensatory hyperactivation. These are primarily used in research settings.
Computed Tomography (CT)
While largely supplanted by MRI in neurodegenerative disease evaluation, CT remains useful for:
- Rapid exclusion of structural lesions (tumors, subdural hematoma, hydrocephalus)
- Assessment of normal-pressure-hydrocephalus with Evans' index measurement
- Screening when MRI is contraindicated (pacemakers, severe claustrophobia)
- Detection of calcification in conditions like Fahr's disease
Single-Photon Emission Computed Tomography (SPECT)
Beyond DaT imaging, perfusion SPECT using ⁹⁹ᵐTcHMPAO or ⁹⁹ᵐTcECD measures regional cerebral blood flow. Perfusion SPECT shows patterns similar to FDG-PET (temporoparietal hypoperfusion in AD, frontal hypoperfusion in FTD) but with lower spatial resolution. Cardiac ¹²³IMIBG scintigraphy demonstrating reduced postganglionic sympathetic innervation supports the diagnosis of lewy-body-dementia and parkinsons.
Emerging and Advanced Techniques
Artificial Intelligence and Deep Learning
Machine learning and deep learning approaches are increasingly applied to neuroimaging data for automated diagnosis, prediction of disease progression, and identification of novel imaging biomarkers. Convolutional neural networks (CNNs) trained on structural MRI can classify Alzheimer's Disease with high accuracy, and multi-modal AI models integrating MRI, PET, and clinical data show promise for precision medicine approaches .
Ultra-High-Field MRI (7T)
7-Tesla MRI provides superior spatial resolution, enabling visualization of hippocampal subfields, cortical layers, and submillimeter brainstem structures. This is particularly valuable for research into selective-neuronal-vulnerability and early microstructural changes.
Magnetic Resonance Spectroscopy (MRS)
MRS measures brain metabolite concentrations non-invasively, including N-acetylaspartate (NAA, a marker of neuronal integrity), myo-inositol (a marker of gliosis), and glutamate/glutamine. Reduced NAA/creatine ratios and elevated myo-inositol are found in neurodegenerative diseases.
Quantitative Susceptibility Mapping (QSM)
QSM quantifies tissue magnetic susceptibility, providing sensitive measures of iron deposition in the basal-ganglia and substantia-nigra. This technique is valuable in parkinsons, huntington-pathway, and NBIA disorders.
Transcranial Sonography (TCS)
Transcranial sonography (TCS) is a non-invasive ultrasound technique used to assess brainstem structures, particularly the substantia-nigra. Substantia nigra hyperechogenicity (increased echogenicity) on TCS is a characteristic finding in Parkinson's Disease, present in approximately 90% of clinically diagnosed PD patients. The sensitivity for detecting prodromal PD in isolated REM sleep behavior disorder (iRBD) is high, making TCS a valuable screening tool for at-risk populations.
TCS findings:
- Substantia nigra hyperechogenicity: Bright echogenic signal from the substantia nigra, reflecting increased iron or neuromelanin content
- Third ventricle width: Correlates with ventricular enlargement in normal pressure hydrocephalus
- Lens ventricle diameter: Assists in differentiating parkinsonian syndromes
TCS advantages include low cost, portability, and lack of radiation. Limitations include bone window quality dependence (approximately 10-15% of patients have inadequate temporal bone windows, especially older females).
Quantitative Movement Analysis
Quantitative movement analysis provides objective, measurable assessments of motor function in movement disorders:
Optical Motion Capture Systems
Marker-based systems using infrared cameras track body position in 3D space. Key assessments include:
- Gait analysis: Step length, cadence, swing/stance phase timing, symmetry
- Postural sway: Center of pressure displacement during standing
- Timed Up-and-Go (TUG): Total time, turn duration, sit-to-stand transitions
Instrumented Timed Up-and-Go (iTUG)The iTUG combines the standard TUG with inertial measurement units (IMUs) to quantify:
- Sit-to-stand phase duration
- Walking velocity and stride length
- Turning dynamics (angular velocity, number of steps)
- Stand-to-sit phase duration
iTUG is highly sensitive to subtle motor impairment in early PD and shows good correlation with MDS-UPDRS scores.
Wearable Device Assessments
Wearable inertial measurement units (IMUs) and accelerometers enable continuous, objective motor monitoring:
Accelerometry and IMU-Based Analysis
- Tremor quantification: Frequency, amplitude, and pattern of rest, postural, and action tremors
- Bradykinesia assessment: Reduced movement amplitude and velocity
- Dyskinesia detection: Pattern recognition distinguishing from voluntary movements
- Freezing of gait (FOG): Detection using accelerometer/gyroscope signatures
Sensors and Placement
- Wrist-worn devices: Quantify tremor, bradykinesia, and dyskinesia of the upper extremities
- Lower back devices: Assess gait, posture, and freezing of gait
- Foot sensors: Step detection, gait timing, and symmetry
Clinical Utility
- Objective documentation of motor fluctuations
- Home monitoring enables assessment outside clinic settings
- Correlation with MDS-UPDRS motor scores
- Sensitive to medication response and disease progression
Research-grade systems (balance masters, instrumented walkways) complement clinical assessment in specialized movement disorder centers.
Clinical Applications and Guidelines
Diagnostic Algorithms
The 2024 International Working Group (IWG) and National Institute on Aging–Alzheimer's Association (NIA-AA) revised criteria for Alzheimer's Disease incorporate neuroimaging biomarkers (amyloid PET, tau PET, MRI atrophy) as core diagnostic features, enabling a biological definition of the disease independent of clinical symptoms .
For parkinsonian syndromes, the Movement Disorder Society criteria incorporate DaT imaging, MRI findings, and cardiac MIBG scintigraphy to support clinical diagnosis.
Clinical Trial Endpoints
Neuroimaging serves as both an enrichment biomarker (identifying eligible participants) and an outcome measure in clinical trials:
- Volumetric MRI: Measures brain atrophy rates as a secondary endpoint
- amyloid-pet: Confirms target engagement of anti-amyloid therapies (amyloid removal)
- Tau PET: Emerging as a measure of downstream neuroprotection
- ARIA monitoring: Required safety imaging during anti-amyloid immunotherapy
The ADNI has established standardized imaging protocols that are now used globally in clinical trials and observational studies .
Limitations and Future Directions
Despite remarkable advances, neuroimaging in neurodegeneration faces several challenges:
- Cost and accessibility: PET imaging remains expensive and geographically limited
- Radiation exposure: PET and SPECT involve ionizing radiation, limiting longitudinal use
- Temporal resolution: Structural MRI changes often lag behind molecular pathology by years
- Specificity: Some tracers (e.g., TSPO PET) lack specificity for disease-relevant targets
- Standardization: Variability in acquisition protocols and analysis methods across centers
Future directions include the development of novel PET tracers for tdp-43, alpha-synuclein, and specific neuroinflammation targets; integration of multi-modal imaging with fluid biomarkers; and the application of AI to enable earlier and more precise diagnosis .
See Also
- [Deep Brain Stimulation](/treatments/deep-brain-stimulation)
- [AIDP: Automated Imaging Differentiation for Parkinsonism](/diagnostics/automated-imaging-differentiation-parkinsonism)
- [Machine Learning MRI for PSP](/diagnostics/psp-ml-imaging-diagnosis)
External Links
- [Alzheimer's Disease Neuroimaging Initiative (ADNI)](http://adni.loni.usc.edu/)
- [ADNI Data](https://ida.loni.usc.edu/)
- [Society of Nuclear Medicine and Molecular Imaging (SNMMI)](https://www.snmmi.org/)
Background
The study of Neuroimaging In Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
[Jack CR Jr, et al., (2024). Alzheimer's Disease as a Clinical-Biological Construct — An International Working Group Recommendation. JAMA Neurology. [PubMed) (2024)](https://pubmed.ncbi.nlm.nih.gov/39483064/)
[Unknown, (n.d.)](https://pubmed.ncbi.nlm.nih.gov/37872430/)
[Ducharme S, et al., (2020). Recommendations to distinguish behavioural variant Frontotemporal Dementia from psychiatric disorders. Brain, 143(6):1632-1650. [DOI: 10.1093/brain/awaa018. [PubMed)) (2020)](https://pubmed.ncbi.nlm.nih.gov/32129844/)
[Pyatigorskaya N, et al, (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/31629653/)
[Veitch DP, et al., (2025). Overview of Alzheimer's Disease Neuroimaging Initiative and future clinical trials. Alzheimer's & Dementia. [DOI:10.1002/alz.14321 (2025)](https://doi.org/10.1002/alz.14321)
[Veitch DP, et al., (2024). The Alzheimer's Disease Neuroimaging Initiative in the era of Alzheimer's Disease treatment: A review. Alzheimer's & Dementia, 20(1):572-604. [DOI: 10.1002/alz.13449. [PubMed)) (2024)](https://pubmed.ncbi.nlm.nih.gov/37698424/)
[Pontecorvo MJ, et al., (2025). Recent advances in neuroimaging of Alzheimer's Disease and related dementias. Alzheimer's & Dementia. [DOI:10.1002/alz.70648 (2025)](https://doi.org/10.1002/alz.70648)
[Defined AH, et al., (2021). Diagnostic power of resting-state fMRI for detection of network connectivity in Alzheimer's Disease and mild cognitive impairment. Human Brain Mapping, 42(9):2941-2956. [DOI: 10.1002/hbm.25369. [PubMed)) (2021)](https://pubmed.ncbi.nlm.nih.gov/33942449/)
[Unknown, Dennis EL, Thompson PM (2014). Functional brain connectivity using fMRI in aging and Alzheimer's Disease. Neuropsychology Review, 24(1):49-62. [DOI: 10.1007/s11065-014-9249-6. [PubMed)) (2014)](https://pubmed.ncbi.nlm.nih.gov/24562737/)
[Vrahatis AG, et al., (2024). AI-driven innovations in Alzheimer's Disease: Integrating early diagnosis, personalized treatment, and prognostic modelling. Ageing Research Reviews, 103:102497. [DOI: 10.1016/j.arr.2024.102497. [PubMed)) (2024)](https://pubmed.ncbi.nlm.nih.gov/39293530/)
[Berg D, et al., (2018). Transcranial sonography in movement disorders. Movement Disorders, 33(11):1684-1692. [DOI: 10.1002/mds.98. [PubMed)) (2018)](https://pubmed.ncbi.nlm.nih.gov/30328173/)
[Shulman LM, et al., (2023). Wearable devices for objective assessment of Parkinson disease. J Parkinsons Dis, 13(5):733-744. [DOI: 10.3233/JPD-230092. [PubMed)) (2023)](https://pubmed.ncbi.nlm.nih.gov/37874128/)
[Salarian A, et al., (2007). iTUG test of gait and turning in Parkinson's disease. J Neurol Neurosurg Psychiatry, 78(8):865-870. [DOI: 10.1136/jnnp.2006.098442. [PubMed)) (2007)](https://pubmed.ncbi.nlm.nih.gov/17043291/)